Table 2.

Incidence rates and adjusted hazard ratios for future cardiovascular events and all-cause mortality associated with baseline high-sensitivity C-reactive protein in the Cardiovascular Inflammation Reduction Trial

	hsCRP (baseline)				Multivariable-adjusted risk (per quartile)
hsCRP (mg/L)	Quartile 1a ≤0.73	Quartile 2a 0.74–1.50	Quartile 3a 1.51–3.41	Quartile 4a ≥3.42	Excluding lipidsa	Including lipidsb
MACE-plus
IR (N)	2.82 (63)	3.58 (77)	4.88 (100)	4.90 (101)	—	—
HR	1.0	1.28	1.73	1.79	1.22	1.11
95% CI	—	0.92–1.79	1.25–2.38	1.28–2.50	1.10–1.35	1.00–1.24
P	—	0.15	0.0009	0.0006	0.0001	0.05
MACE
IR (N)	2.21 (50)	2.89 (63)	4.10 (85)	4.02 (84)	—	—
HR	1.0	1.31	1.83	1.88	1.24	1.12
95% CI	—	0.90–1.91	1.28–2.61	1.30–2.73	1.11–1.39	1.00–1.26
P	—	0.15	0.0009	0.0008	0.0002	0.05
Myocardial infarction
IR (N)	1.58 (36)	1.73 (38)	2.68 (56)	2.65 (56)	—	—
HR	1.0	1.11	1.71	1.83	1.25	1.14
95% CI	—	0.70–1.75	1.12–2.63	1.17–2.85	1.09–1.44	0.99–1.32
P	—	0.67	0.01	0.008	0.002	0.08
Stroke
IR (N)	0.39 (9)	0.54 (12)	0.75 (16)	0.78 (17)	—	—
HR	1.0	1.40	1.84	1.85	1.22	1.04
95% CI	—	0.59–3.33	0.80–4.23	0.79–4.36	0.94–1.58	0.79–1.36
P	—	0.45	0.15	0.16	0.13	0.79
All-cause mortality
IR (N)	1.46 (35)	1.49 (35)	1.92 (44)	1.72 (40)	—	—
HR	1.0	0.99	1.19	1.14	1.06	1.00
95% CI	—	0.61–1.58	0.76–1.88	0.71–1.85	0.91–1.24	0.85–1.17
P	—	0.99	0.44	0.59	0.44	0.95

CI, confidence interval; HR, hazard ratio; IR, incidence rate (per 100 person-years); MACE, major adverse cardiovascular events (non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); MACE-plus, MACE plus hospitalization for unstable angina requiring urgent revascularization.

^aAdjusted for age, gender, smoking status, body mass index, and blood pressure and stratified on diabetes and or metabolic syndrome.

^bAdditionally adjusted for total cholesterol and high-density lipoprotein cholesterol.